Earnings ·
Reports Q3 net loss of $0.15 per share as cash drops to $9.9M
ATRAAtara Biotherapeutics, Inc.
Atara Biotherapeutics reported a third-quarter 2026 net loss of $2.2 million, or $0.15 per share, compared to a $4.3 million loss in the prior year period. Total revenues fell to $1.2 million from $3.5 million, primarily due to the absence of one-time clinical inventory sales. The company reduced its cash and short-term investments to $9.9 million while maintaining a nine-month operating expense reduction of approximately 83%. Atara also announced that the FDA accepted the resubmission for the tabelecleucel BLA, setting a PDUFA target action date of March 31, 2027. The company expects its current cash position to fund operations into mid-2027. Atara Biotherapeutics develops allogeneic T-cell immunotherapies for cancer and autoimmune diseases.